Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (451-460 of 744) with videos related to

Pageof 75
Sort By:
Pigment Cell & Melanoma Research|December 24, 2010
A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation statusMarie C Zipser, Ossia M Eichhoff, Daniel S Widmer, et al.
The Journal of Investigative Dermatology|October 30, 2009
ADAM10 is upregulated in melanoma metastasis compared with primary melanomaSophia B Lee, Anja Schramme, Kai Doberstein, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2006
[Brief guidelines: malignant melanoma of the skin]Claus Garbe, Axel Hauschild, Matthias Volkenandt, et al.
International Journal of Cancer|September 25, 2008
Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathyAlexandr V Bazhin, Claudia Dalke, Nadine Willner, et al.
Oncoimmunology|August 8, 2020
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferationIeva Saulite, Desislava Ignatova, Yun-Tsan Chang, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2021
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastasesMarie-Luise Hilbers, Florentia Dimitriou, Peter Lau, et al.
Cell Reports. Medicine|June 28, 2024
Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistanceJelena Vasilevska, Phil Fang Cheng, Julia Lehmann, et al.
BMC Medical Informatics and Decision Making|October 31, 2018
SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinicsFranziska Singer, Anja Irmisch, Nora C Toussaint, et al.
Cancers|May 14, 2022
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced MelanomaKrisztian Homicsko, Reinhard Dummer, Christoph Hoeller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> -mutant Solid TumorsRyan J Sullivan, Jeffrey Weber, Sapna Patel, et al.
Pageof 75

Showing results (451-460 of 744) with videos related to

Sort By:
Pageof 75
Pigment Cell & Melanoma Research|December 24, 2010
A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation statusMarie C Zipser, Ossia M Eichhoff, Daniel S Widmer, et al.
The Journal of Investigative Dermatology|October 30, 2009
ADAM10 is upregulated in melanoma metastasis compared with primary melanomaSophia B Lee, Anja Schramme, Kai Doberstein, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2006
[Brief guidelines: malignant melanoma of the skin]Claus Garbe, Axel Hauschild, Matthias Volkenandt, et al.
International Journal of Cancer|September 25, 2008
Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathyAlexandr V Bazhin, Claudia Dalke, Nadine Willner, et al.
Oncoimmunology|August 8, 2020
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferationIeva Saulite, Desislava Ignatova, Yun-Tsan Chang, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2021
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastasesMarie-Luise Hilbers, Florentia Dimitriou, Peter Lau, et al.
Cell Reports. Medicine|June 28, 2024
Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistanceJelena Vasilevska, Phil Fang Cheng, Julia Lehmann, et al.
BMC Medical Informatics and Decision Making|October 31, 2018
SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinicsFranziska Singer, Anja Irmisch, Nora C Toussaint, et al.
Cancers|May 14, 2022
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced MelanomaKrisztian Homicsko, Reinhard Dummer, Christoph Hoeller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> -mutant Solid TumorsRyan J Sullivan, Jeffrey Weber, Sapna Patel, et al.
Pageof 75